What is a data trial?
If you’ve never had a serious health issue you may be unaware of the 30 million people in the US with undiagnosed diseases. You may also be unaware that the third leading cause of death in the US is medical errors.
For those who are critically or chronically ill, exorbitant medical bills add to their stress. In fact, the number one cause of personal bankruptcy in the US is not rampant credit card spending or housing debt — it’s medical bills.
The healthcare system has not only become unfixable but it is leaving people making unhealthy choices and turning people into medical and financial refugees.
While it is a 3 trillion dollar industry, the healthcare system has unmatched needs. It is in search of new and better models moving towards value-based care for better quality and better outcomes.
The health economics of personal medical data is currently inefficient because clinical research is a slow and costly process with data of a particular type often fragmented across many different parties.
Your health data is valuable, it is even more valuable in its longitude and completeness. Health data collected over time and analyzed in large quantities can yield unprecedented value not only for you but for the scientific community. The idea of providing people with the ability to have control over their medical assets, and scientists the ability to solve pressing medical problems at scale might be possible because of the convergence of precision medicine (or multi-omics data approach), AI and blockchain.
One important aspect of our platform is that individuals are in control of their data, they decide when to share by participating in a data trial via an explicit opt-in, and the data is de-identified for data scientists to build predictive models.
doc.ai Enabled Data Trials
Today our health data lives all over the place — with payers, providers, physicians, pharmacists, and governments. It is fragmented and hard to access. We blindly trust those who own our personal information and medical records, but our data is sold to third parties and our records are hacked.
At doc.ai we have built to enable data trials. We have created a decentralized multi-party life science platform that connects real-world data at large scale and streamlines collaborations between participants, research sponsors and the global community of data scientists that utilize deep learning algorithms to achieve more precise predictive modeling of complex disease. It is designed for the value to be re-distributed directly to you. We do this because it is your data and it is the right thing to do.
Bottom-up Data Trials
Imagine a world where you could participate in crowd-backed data trials, allow your data to be securely shared using a “smart contract”, unleash AI-powered predictions with an assurance that your holistic circumstances have been taken into account, and earn financial compensations for your efforts, all while advancing the health of generations to come.
If you like what you’re reading, stay tuned we have very exciting things to share in the next couple of weeks!
Join our next developer meeting!
Our focus will be the BLOCKCHAIN and the testnet for our NEURON TOKEN (NRN).
Be among the very first to play with our NRN token:)
Food and Drinks provided
Check code we’ve released on our GitHub
*IFTF is a non-profit think tank celebrating its 50th year of strategic foresight.
We have expanded our team and this month we’re welcoming 4 new team members, with backgrounds in ML/DL and full stack engineering, they are ready to further support doc.ai ‘s mission.
Fun fact: one of them actually followed the Fast.ai deep learning online course founded by our very own doc.ai Chief Science Officer Jeremy Howard and co-founder Rachel Thomas.
Fast.ai is dedicated to making the power of deep learning accessible to all, more than 100,000 coders have followed the course already. Check it out, it is really cool and you’ll connect with great people too.
“Fast.ai… can actually get smart, motivated students to the point of being able to create industrial-grade ML deployments”
-Harvard Business Review — The Business of Artificial Intelligence.
If you’re interested we’re still hiring, check our positions here .